01 Adoption of Platform-based Molecule ManufacturingContract manufacturing organizations are increasingly developing standardized platform manufacturing processes that allow multiple biologics with similar molecular characteristics to be produced using common process templates. This reduces technology transfer timelines and regulatory validation requirements while improving manufacturing flexibility. In 2025, Samsung Biologics launched its ExellenS manufacturing framework, standardizing equipment and process architecture to accelerate client onboarding and technology transfers across production facilities.
02 Integration of Continuous Process Development Before Commercial Scale-upA key contract manufacturing organization market trend is the integration of continuous process development during early-stage manufacturing instead of conventional batch optimization. CMOs are implementing flow chemistry, continuous crystallization, and integrated analytical monitoring to establish scalable commercial processes earlier, minimizing process redevelopment risks, reducing manufacturing variability, and accelerating regulatory readiness for complex pharmaceutical products.
01 The contract manufacturing organization market forecasts continued investments driven by increasing pharmaceutical outsourcing, biologics manufacturing expansion, advanced therapy production, and digital manufacturing capabilities. Investors are focusing on CMOs with specialized expertise in biologics, cell and gene therapies, and high-value manufacturing infrastructure. Rising demand for flexible production capacity, regulatory compliance, and integrated development services is further accelerating funding and capital investment activities.
02 Key Investment and Funding Activities in Contract Manufacturing Organization Market, 2025CompanyFunding/Investment (USD)DetailsResilienceUp to USD 825 MillionIn November 2025, the company secured up to USD 825 million in long-term financing from Oak Hill Advisors to expand its CDMO manufacturing operations and strengthen its biomanufacturing network.Aragen Life SciencesUSD 100 MillionIn January 2025, the company received a USD 100 million investment from Quadria Capital to expand its CRDMO/CDMO capabilities, manufacturing infrastructure, and global pharmaceutical services.
01 Expansion of Dedicated High-potency ADC Manufacturing Suites and Increasing Number of Emerging Biotechnology Companies Drives MarketContract manufacturing organizations are increasingly establishing dedicated facilities exclusively for antibody-drug conjugate (ADC) production, separating cytotoxic payload handling from conventional biologics manufacturing. This specialization improves containment, occupational safety, and regulatory compliance while supporting growing oncology pipelines. In October 2025, SK pharmteco announced a USD 260 million investment in peptide and high-potency manufacturing capabilities, including eight production trains and cGMP facilities, reflecting accelerating demand for specialized CDMO infrastructure, which, in turn, supports market growth.The growing number of emerging biotechnology companies with limited in-house manufacturing infrastructure is a major market driver, increasing demand for end-to-end CMO services. Early-stage developers increasingly outsource formulation development, clinical manufacturing, fill-finish operations, analytical testing, and commercial production to accelerate product commercialization while preserving capital for research activities. Additionally, pharmaceutical companies are adopting asset-light manufacturing strategies to improve supply chain resilience and rapidly respond to changing market demand. This continued shift toward strategic outsourcing is strengthening long-term growth opportunities across the contract manufacturing organization market.
01 Complex Technology Transfer Requirements and High Regulatory Compliance Costs Restrain Market ExpansionTechnology transfer between pharmaceutical sponsors and contract manufacturing organizations is often complex, requiring extensive process validation, analytical method qualification, equipment compatibility assessments, and regulatory documentation. Even minor variations in manufacturing parameters can affect product quality, particularly for biologics and sterile injectables. These challenges increase development timelines, operational costs, and regulatory risks, making technology transfer a significant restraint for contract manufacturing organizations.The contract manufacturing organization market is also constrained by the high cost of maintaining global regulatory compliance and specialized manufacturing infrastructure. CMOs must continuously invest in GMP-certified facilities, digital quality systems, contamination control technologies, and frequent regulatory inspections to meet evolving international standards. Rising compliance expenses, workforce training requirements, and capital-intensive facility upgrades place pressure on operating margins while limiting expansion opportunities, particularly for small and mid-sized contract manufacturers.
01 Growth of Integrated Cell & Gene Therapy Manufacturing and Increasing Deployment of Hybrid CDMO Models Open New Revenue Avenues for Market PlayersThe rapid advancement of cell and gene therapies is creating growth opportunities for contract manufacturing organizations to provide integrated development, viral vector production, cell processing, fill-finish, and commercial manufacturing services. Emerging biotechnology companies increasingly prefer single-source manufacturing partners capable of supporting products from preclinical development through commercialization, reducing technology transfer complexity while accelerating regulatory submissions and market entry.The increasing adoption of hybrid contract development and manufacturing organization models is creating significant opportunities for market players. These models combine proprietary formulation platforms, standardized development technologies, and conventional contract manufacturing within a single service offering. By leveraging validated platform technologies alongside customized manufacturing, CDMOs can reduce technology transfer timelines, accelerate product development, minimize process risks, and improve operational efficiency. This integrated approach enables pharmaceutical and biotechnology companies to shorten commercialization timelines while allowing CDMOs to expand service portfolios, strengthen long-term client relationships, and capture higher-value manufacturing contracts across multiple therapeutic modalities.
01 Multi-client Manufacturing Capacity and Complex Cross-network Technology Transfer Challenges Market GrowthThe growing shift toward personalized medicines, orphan drugs, and advanced biologics is creating manufacturing environments with numerous low-volume, high-value production campaigns. CMOs must frequently change production configurations, validate equipment between clients, and efficiently schedule shared manufacturing assets. Maintaining operational flexibility without affecting delivery timelines, product quality, or facility utilization becomes increasingly difficult as client portfolios diversify across multiple therapeutic modalities.Technology transfer across multiple global manufacturing sites remains a major challenge for contract manufacturing organizations. Differences in equipment configuration, process automation systems, analytical methods, and regional regulatory expectations make process replication highly complex. Even minor manufacturing variations can require additional validation and comparability studies, increase development timelines, and increase operational costs while making it difficult to achieve consistent product quality across geographically distributed production networks.
June 2026 Siegfried inaugurated a large-scale drug-substance facility in Minden, Germany, adding 100 m³ reactor capacity for complex and high-containment manufacturing
March 2026 Samsung Biologics completed acquisition of GSK’s Rockville facility, adding 60,000 liters of drug-substance capacity and establishing its first US manufacturing presence.
March 2026 SK pharmteco and Prozomix announced a strategic collaboration integrating Prozomix’s 6,000-plus biocatalyst library into SK pharmteco’s small-molecule CDMO services.
March 2026 Lonza and Genetix Biotherapeutics extended their commercial manufacturing agreement for ZYNTEGLO, expanding capacity at Lonza’s Houston cell therapy facility.
October 2025 LOTTE BIOLOGICS and SK pharmteco signed an LOI for strategic collaboration to provide integrated ADC CDMO services covering antibody drug substance, linker-payload, and bioconjugation.
September 2025 Thermo Fisher Scientific completed the acquisition of Sanofi’s Ridgefield, New Jersey sterile fill-finish and packaging site, expanding US CDMO drug-product manufacturing capacity.